NCT06788509 2026-04-13A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringJanssen Research & Development, LLCPhase 1 Enrolling by invitation120 enrolled
NCT07218003 2026-03-23A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Rondo TherapeuticsPhase 1 Enrolling by invitation149 enrolled
NCT06674538 2025-09-22Clinical Trial to Treat Stage IV Cancer PatientsMoonshot AntibodiesPhase 1 Enrolling by invitation12 enrolled